Heron Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 126
- Market Cap
- $292.7M
- Website
- http://www.herontx.com
Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery
Phase 2
Completed
- Conditions
- Postoperative Pain
- Interventions
- Drug: HTX-011ADrug: PlaceboDrug: HTX-011BDrug: HTX-002Drug: Bupivicaine HCl
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 277
- Registration Number
- NCT02689258
A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy
Phase 2
Completed
- Conditions
- Postoperative Pain
- Interventions
- Drug: Bupivacaine HCI (Marcaine)Drug: HTX-011Drug: HTX-011ADrug: HTX-011BDrug: HTX-002Drug: PlaceboDrug: HTX-009
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 463
- Registration Number
- NCT02504580
A Phase 2, Two-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
Phase 2
Completed
- Conditions
- Analgesia
- Interventions
- Drug: HTX-011Drug: Placebo
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT02471898
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
Phase 3
Completed
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Drug: APF530Drug: OndansetronDrug: Ondansetron placeboDrug: APF530 placeboDrug: FosaprepitantDrug: Dexamethasone
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 942
- Registration Number
- NCT02106494
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HAL, Pheonix, Arizona, United States
🇺🇸Northern Indiana Research, South Bend, Indiana, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
Completed
- Conditions
- Healthy
- Interventions
- Drug: Withdraw treatment
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT01416259
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Phase 3
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificNausea and Vomiting
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 1428
- Registration Number
- NCT00343460
- Locations
- 🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Palo Verde Hematology Oncology - Glendale, Glendale, Arizona, United States
🇺🇸Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath